NovaBay Pharmaceuticals, Inc.

NYSEAM:NBY Voorraadrapport

Marktkapitalisatie: US$3.7m

NovaBay Pharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

NovaBay Pharmaceuticals is forecast to grow earnings and revenue by 70.5% and 7.7% per annum respectively while EPS is expected to grow by 130.4% per annum.

Belangrijke informatie

70.5%

Groei van de winst

130.4%

Groei van de winst per aandeel

Pharmaceuticals winstgroei23.7%
Inkomstengroei7.7%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt30 Aug 2024

Recente toekomstige groei-updates

Recent updates

We Think NovaBay Pharmaceuticals (NYSEMKT:NBY) Can Afford To Drive Business Growth

Mar 29
We Think NovaBay Pharmaceuticals (NYSEMKT:NBY) Can Afford To Drive Business Growth

Winst- en omzetgroeiprognoses

NYSEAM:NBY - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202616-3N/A01
12/31/202514-4N/A-32
12/31/202411-6N/A-42
6/30/202414-17-3-3N/A
3/31/202415-19-4-4N/A
12/31/202315-17-4-4N/A
9/30/202313-15-5-5N/A
6/30/202313-19-6-6N/A
3/31/202313-17-6-6N/A
12/31/202214-16-7-7N/A
9/30/202214-9-10-10N/A
6/30/202213-5-10-10N/A
3/31/202212-5-10-10N/A
12/31/202110-7-9-9N/A
9/30/20219-7-6-6N/A
6/30/20218-8-6-6N/A
3/31/202110-11-5-5N/A
12/31/202010-11-5-5N/A
9/30/202010-13-5-5N/A
6/30/20209-10-5-5N/A
3/31/20207-8-6-6N/A
12/31/20197-10-8-8N/A
9/30/20198-8-9-8N/A
6/30/201910-10-9-9N/A
3/31/201911-9-8-8N/A
12/31/201813-7-6-6N/A
9/30/201815-4-7-7N/A
6/30/201816-5-5-5N/A
3/31/201817-6N/A-5N/A
12/31/201718-7N/A-6N/A
9/30/201716-10N/A-4N/A
6/30/201715-11N/A-8N/A
3/31/201714-12N/A-9N/A
12/31/201612-13N/A-12N/A
9/30/20169-16N/A-16N/A
6/30/20167-17N/A-16N/A
3/31/20166-19N/A-19N/A
12/31/20154-19N/A-19N/A
9/30/20153-19N/A-18N/A
6/30/20152-18N/A-17N/A
3/31/20151-16N/A-15N/A
12/31/20141-15N/A-15N/A
9/30/20141-15N/A-16N/A
6/30/20142-14N/A-15N/A
3/31/20143-16N/A-14N/A
12/31/20133-16N/A-13N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: NBY is forecast to remain unprofitable over the next 3 years.

Winst versus markt: NBY is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: NBY is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: NBY's revenue (7.7% per year) is forecast to grow slower than the US market (8.9% per year).

Hoge groei-inkomsten: NBY's revenue (7.7% per year) is forecast to grow slower than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if NBY's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven